Article summary
As potential approvals of psychedelic therapies draw closer, attention is increasingly turning to what their real-world delivery might look like. While many details remain unknown, one thing appears increasingly likely: Risk Evaluation and Mitigation Strategies (REMS) will play a significant role in shaping how FDA-approved psychedelic therapies are delivered. REMS are additional safeguards that the […]
Continue to the original publication for the complete article.